Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 8, 2024

Integrating New PAH Therapies into Clinical Practice

An expert on pulmonary arterial hypertension discusses how sotatercept might fit into current treatment paradigms and key factors that should guide clinical decision-making.

Episodes in this series

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 1 Evolving Guidelines for PAH Treatment

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 2 New Therapeutic Frontiers in PAH

Ioana Preston, MD, a pulmonologist

EP. 3 Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

Ioana Preston, MD, a pulmonologist

EP. 4 Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

Marius Hoeper, MD, an expert on PAH

EP. 5 Breaking Down the PAH Cost Burden

Marius Hoeper, MD, an expert on PAH

EP. 6 A New Era in PAH Treatment?

"Clinical Evidence for Emerging PAH Therapies"

EP. 7 Clinical Evidence for Emerging PAH Therapies

"Integrating New PAH Therapies into Clinical Practice"

EP. 8 Integrating New PAH Therapies into Clinical Practice

Ioana Preston, MD, a pulmonologist

EP. 9 Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

Marius Hoeper, MD, an expert on PAH

EP. 10 FDA Approves Sotatercept for Pulmonary Arterial Hypertension

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 11 Overcoming Barriers to Better Patient Outcomes in PAH

Ioana Preston, MD, a pulmonologist

EP. 12 Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

Marius Hoeper, MD, an expert on PAH

EP. 13 Optimizing PAH Care Delivery for Better Outcomes

Marius Hoeper, MD, an expert on PAH

EP. 14 Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following questions:

Sotatercept, a new treatment for PAH, recently received FDA approval in April 2024. How do you see this new therapy, as well as other emerging pulmonary arterial hypertension (PAH) treatments, fitting into the current treatment paradigm for PAH?
What key factors should guide clinicians in determining the appropriate use of these new therapies in clinical practice?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

How Often Do Health Insurers Deny Doctor-Recommended Care?

Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes